Menu Search
Equities

medmix AG

8KQ:BRN

medmix AG

Actions
  • Price (CHF)9.95
  • Today's Change0.09 / 0.91%
  • Shares traded94.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medmix Systems AG is a Switzerland-based company active in manufacturing of high-precision delivery devices. The Company operates in business areas such as: the dental segment, which provides MIXPAC and transcodent - system solutions that are used to dose, mix and apply various types of dental materials; drug delivery- solutions for the dosage and application of drugs; a surgical segment which provides devices for bone regeneration and tissue healing; an industry segment that specializes in the mixing and dosing of sealants and adhesives through IXPAC , COX and MK; and a beauty segment in which it produces cosmetic applicators through the GEKA brand.

  • Revenue in CHF (TTM)479.70m
  • Net income in CHF-1.80m
  • Incorporated2021
  • Employees2.70k
  • Location
    medmix AGNeuhofstrasse 20BAAR 6340SwitzerlandCHE
  • Phone+41 417237300
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.